{"id":"https://openalex.org/W4386701655","doi":"https://doi.org/10.1097/cad.0000000000001442","title":"Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells","display_name":"Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells","publication_year":2023,"publication_date":"2023-08-31","ids":{"openalex":"https://openalex.org/W4386701655","doi":"https://doi.org/10.1097/cad.0000000000001442","pmid":"https://pubmed.ncbi.nlm.nih.gov/37703296"},"language":"en","primary_location":{"id":"doi:10.1097/cad.0000000000001442","doi":"https://doi.org/10.1097/cad.0000000000001442","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001442","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113836377","display_name":"Laurence A. Booth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laurence Booth","raw_affiliation_strings":["Department of Biochemistry and Molecular Biology, Virginia Commonwealth University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080982053","display_name":"Andrew Stewart Poklepovic","orcid":"https://orcid.org/0000-0002-4015-5037","observed_orcids":["https://orcid.org/0000-0002-4015-5037"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Poklepovic","raw_affiliation_strings":["Medicine, Virginia Commonwealth University, Richmond Virgina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine, Virginia Commonwealth University, Richmond Virgina","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037758372","display_name":"John F. Hancock","orcid":"https://orcid.org/0000-0003-0542-4710","observed_orcids":["https://orcid.org/0000-0003-0542-4710"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John F. Hancock","raw_affiliation_strings":["Department of Integrative Biology and Pharmacology, McGoven Medical School, University of Texas Health Science Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Integrative Biology and Pharmacology, McGoven Medical School, University of Texas Health Science Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069980003","display_name":"Paul Dent","orcid":"https://orcid.org/0000-0001-6948-1875","observed_orcids":["https://orcid.org/0000-0001-6948-1875"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul Dent","raw_affiliation_strings":["Department of Biochemistry and Molecular Biology, Virginia Commonwealth University","to Paul Dent, PhD, Department of Biochemistry and Molecular Biology, Massey Cancer Center, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA, Tel: +804 539 2582"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University","institution_ids":["https://openalex.org/I184840846"]},{"raw_affiliation_string":"to Paul Dent, PhD, Department of Biochemistry and Molecular Biology, Massey Cancer Center, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA, Tel: +804 539 2582","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5069980003"],"corresponding_institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"],"apc_list":null,"apc_paid":null,"fwci":0.55,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.66911277,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"34","issue":"9","first_page":"1025","last_page":"1034"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neratinib","display_name":"neratinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/ras-mutations","display_name":"RAS mutations","score":0.765999972820282},{"id":"https://openalex.org/keywords/kras","display_name":"KRAS","score":0.9020000100135803},{"id":"https://openalex.org/keywords/nras","display_name":"NRAS","score":0.9940000176429749},{"id":"https://openalex.org/keywords/egf-receptor","display_name":"EGF receptor","score":0.6629999876022339},{"id":"https://openalex.org/keywords/erbb2","display_name":"ERBB2","score":0.6449999809265137},{"id":"https://openalex.org/keywords/erbb4","display_name":"ErbB4","score":0.9649999737739563},{"id":"https://openalex.org/keywords/mtor-signaling","display_name":"mTOR signaling","score":0.8299999833106995},{"id":"https://openalex.org/keywords/autophagy","display_name":"autophagy","score":0.8970000147819519},{"id":"https://openalex.org/keywords/beclin-1","display_name":"Beclin-1","score":0.7120000123977661},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.8539999723434448},{"id":"https://openalex.org/keywords/bcl-xl","display_name":"Bcl-xL","score":0.9750000238418579},{"id":"https://openalex.org/keywords/prosurvival-signaling","display_name":"survival signaling","score":0.40700000524520874},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7390000224113464}],"concepts":[{"id":"https://openalex.org/C2779413316","wikidata":"https://www.wikidata.org/wiki/Q6995920","display_name":"Neratinib","level":5,"score":0.8847880363464355},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.6041496396064758},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5868176817893982},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.5711178183555603},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4863894283771515},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.48216861486434937},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.4411364197731018},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4002682864665985},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37742841243743896},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.3580330014228821},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32847535610198975},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30493253469467163},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.2628837823867798},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.20494124293327332},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17543691396713257},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.15895423293113708},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.14002081751823425},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.10765832662582397},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068437","descriptor_name":"Pemetrexed","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/cad.0000000000001442","doi":"https://doi.org/10.1097/cad.0000000000001442","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001442","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:37703296","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37703296","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"},{"id":"pmh:oai:digitalcommons.library.tmc.edu:uthmed_docs-4401","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.library.tmc.edu/uthmed_docs/3485","pdf_url":null,"source":{"id":"https://openalex.org/S4377196655","display_name":"Digital Commons-TMC (Texas Medical Center)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1337852284","host_organization_name":"Texas Medical Center","host_organization_lineage":["https://openalex.org/I1337852284"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Faculty, Staff and Student Publications","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1525027209","https://openalex.org/W2091694499","https://openalex.org/W2157912474","https://openalex.org/W2327188447","https://openalex.org/W2762797953","https://openalex.org/W2778263326","https://openalex.org/W2789574007","https://openalex.org/W2891563533","https://openalex.org/W2896322150","https://openalex.org/W2906325618","https://openalex.org/W2921771746","https://openalex.org/W2953798516","https://openalex.org/W2997576638","https://openalex.org/W3000191756","https://openalex.org/W3034136661","https://openalex.org/W3094102895","https://openalex.org/W3096158460","https://openalex.org/W3129384848","https://openalex.org/W3164999895","https://openalex.org/W3210143298","https://openalex.org/W4220814318","https://openalex.org/W4223604353","https://openalex.org/W4229376968","https://openalex.org/W4291792391"],"related_works":["https://openalex.org/W3164999895","https://openalex.org/W2339915715","https://openalex.org/W2134964659","https://openalex.org/W3194452238","https://openalex.org/W2145842917","https://openalex.org/W2325539731","https://openalex.org/W7223332749","https://openalex.org/W2997576638","https://openalex.org/W2170830310","https://openalex.org/W2138503145"],"abstract_inverted_index":{"We":[0],"previously":[1],"demonstrated":[2],"that":[3,23,43],"neratinib":[4,50,243,260],"interacted":[5,89],"with":[6],"pemetrexed":[7,55,88,245],"to":[8,32,40,45,57,96,252,259],"kill":[9,58,97],"non-small":[10],"cell":[11],"lung":[12],"cancer":[13],"(NSCLC)":[14],"cells.":[15],"From":[16],"developing":[17],"other":[18],"drug":[19,34,131,176],"combinations,":[20],"we":[21],"observed":[22],"several":[24],"days":[25],"following":[26],"exposure,":[27],"cells":[28,60,256],"activated":[29,121,124],"survival":[30,217],"mechanisms":[31,42,241],"counteract":[33],"toxicity.":[35],"The":[36,175],"present":[37],"studies":[38,248],"attempted":[39],"define":[41],"evolve":[44],"reduce":[46],"the":[47,109,135,145,148,150,164,188,191,236],"efficacy":[48],"of":[49,111,127,147,154,166,169,190,201,208,216,238],"and":[51,54,70,82,87,101,152,157,173,180,203,207,210,244,261],"pemetrexed.":[52,262],"Neratinib":[53,86],"synergized":[56],"NSCLC":[59,255],"expressing":[61],"wild-type":[62],"RAS":[63,193],"proteins,":[64],"mutant":[65,73,77,128],"KRAS":[66,114,129,179],"(G12S;":[67],"Q61H;":[68],"G12A":[69],"G12C)":[71],"or":[72,76,123,223,225],"NRAS":[74,181],"(Q61K)":[75],"ERBB1":[78],"(L858R;":[79],"L858R":[80],"T790M":[81],"exon":[83],"19":[84],"deletion).":[85],"in":[90,108,144,187,226],"a":[91,103],"greater":[92],"than":[93,119],"additive":[94],"fashion":[95],"after":[98,102,242],"24":[99,105,142,184],"h,":[100,185],"further":[104],"h":[106,137,143],"culture":[107,140],"absence":[110,146,189],"drugs.":[112],"Mutant":[113],"G12V":[115],"was":[116],"more":[117],"cytoprotective":[118],"either":[120],"MEK1":[122],"AKT.":[125],"Knockdown":[126],"reduced":[130,178],"combination":[132,177],"killing":[133],"at":[134],"48":[136,198],"timepoint.":[138],"Despite":[139],"for":[141,183],"drugs,":[149,192],"expression":[151],"activities":[153,165],"ERBB1,":[155],"ERBB2":[156],"ERBB4":[158],"remained":[159,205],"significantly":[160],"lower":[161],"as":[162],"did":[163],"mammalian":[167],"target":[168],"rapamycin":[170],"(mTOR)":[171],"C1":[172],"mTORC2.":[174],"levels":[182,194],"however,":[186],"had":[195],"normalized":[196],"by":[197,219],"h.":[199],"Expression":[200],"Beclin1":[202],"ATG5":[204],"elevated":[206],"MCL1":[209],"BCL-XL":[211],"lower.":[212],"No":[213],"evolutionary":[214],"activations":[215],"signaling":[218,228],"ERBB3,":[220],"c-KIT,":[221],"c-MET":[222],"PDGFR\u03b2":[224],"intracellular":[227],"pathways":[229],"were":[230],"observed.":[231],"These":[232],"findings":[233],"argue":[234],"against":[235],"development":[237],"'early'":[239],"resistance":[240],"exposure.":[246],"Future":[247],"will":[249],"be":[250],"required":[251],"understand":[253],"how":[254],"become":[257],"resistant":[258]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-09-14T00:00:00"}